Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR(V)-EDV-Dox in recurrent glioblastoma
NCT02766699Phase 1Completed
- Sponsor
- EnGeneIC
- Start
- Oct 2016
- Primary completion
- Aug 2021
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EGFR(V)-EDV-Dox in glioblastoma (GBM), sponsored by EnGeneIC. Primary endpoint: Safety outcome measures. Started Oct 2016; status: completed.
02
Drugs
EGFR(V)-EDV-Dox
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02766699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02766699.